SEC Comment Letter 0000000000-23-003513 to Syros Pharmaceuticals, Inc. (SYRS) (CIK 0001556263)
Syros Pharmaceuticals, Inc. (SYRS) (CIK 0001556263)
Date: April 7, 2023 · CIK: 0001556263 · Accession: 0000000000-23-003513
AI Filing Summary & Sentiment
File numbers found in text: 333-271160
Letter
United States securities and exchange commission logo April 7, 2023 Gerald Quirk Chief Legal Officer Syros Pharmaceuticals, Inc. 35 Cambridge Park Drive, 4th Floor Cambridge, MA 02140 Re:Syros Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed April 6, 2023 File No. 333-271160 Dear Gerald Quirk: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Cynthia T. Mazareas
Show Raw Text
United States securities and exchange commission logo
April 7, 2023
Gerald Quirk
Chief Legal Officer
Syros Pharmaceuticals, Inc.
35 Cambridge Park Drive, 4th Floor
Cambridge, MA 02140
Re:Syros Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed April 6, 2023
File No. 333-271160
Dear Gerald Quirk:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Cynthia T. Mazareas